Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Exelixis Up On Positive Kidney Cancer Data On Cabometyx

Published 06/07/2016, 03:46 AM
Updated 07/09/2023, 06:31 AM
PFE
-
JNJ
-
ABT
-
EXEL
-

Exelixis, Inc. (NASDAQ:EXEL) , along with its partner Ipsen, announced positive data from subgroup analyses of the METEOR trial on Cabometyx (tablet formulation of cabozantinib) at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting.

The trial compared Cabometyx with Afinitor in patients suffering from advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.

Data from the studies showed that treatment with Cabometyx improved progression-free survival (PFS) and overall survival (OS) in patients who had bone metastases at baseline.

Trial data also showed that the benefits of Cabometyx in PFS and OS were independent of the presence of bone metastases, prior anti-PD-1/PD-L1 therapy, and the type of prior vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) therapy. They were, in fact, consistent regardless of prior treatment, location and extent of tumor metastases.

Shares of the company gained 11.2% on the news.

We remind investors that Cabometyx was approved by the FDA in Apr 2016 for the treatment of patients with advanced RCC who have received prior anti-angiogenic therapy.

The FDA approval of Cabometyx for RCC is a major boost for the company and will drive the top line in the forthcoming quarters.

Meanwhile, the European Medicines Agency (EMA) has accepted a Marketing Authorisation Application (MAA) for Cabometyx for review in the same indication. Upon a potential approval, the drug would be marketed in the EU by Ipsen. The MAA was granted accelerated assessment by the EMA’s Committee for Medicinal Products for Human Use (CHMP), which translates to a review period of 150 days instead of the standard review period of 210 days.

Cometriq, the capsule form of cabozantinib is approved for the treatment of progressive, metastatic medullary thyroid cancer.

Exelixis currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Pfizer Inc. (NYSE:PFE) , Johnson & Johnson (NYSE:JNJ) and Abbott Laboratories (NYSE:ABT) . While Pfizer sports a Zacks Rank #1 (Strong Buy), Johnson & Johnson and Abbott Labs carry a Zacks Rank #2 (Buy).



PFIZER INC (PFE): Free Stock Analysis Report

JOHNSON & JOHNS (JNJ): Free Stock Analysis Report

ABBOTT LABS (ABT): Free Stock Analysis Report

EXELIXIS INC (EXEL): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.